
New York has increased PFAS regulations as understanding has improved
PFAS, formally per- and polyflouroalkyl substances, are a class of chemicals that were heavily used from the 1940s to the late 2000s, although they persist in some applications to this day. Produced by companies like 3M, contamination can come from a variety of sources and typically results in contamination of the water table.
They're known as 'forever chemicals' because there's no way to fully remove them from the water or soil they contaminate, and they don't break down fast enough to disappear over even centuries. They build up in the environment including plants and animals, causing health problems for them and also moving up the food chain.
People who consume high levels of PFAS, or a smaller volume over a long period of time, can develop rare cancers, pre-eclampsia or a whole host of other chronic illnesses and diseases.
In 2016, New York was one of the first states to urge the federal Environmental Protection Agency to acknowledge that PFAS contamination is a major concern — joined with Vermont and New Hampshire, they pushed the EPA to implement its first health advisory for PFAS consumption later that year.
New York was the first state in the country to regulate PFAS, specifically the chemical perflourooctanoic acid or PFOA, according to the state Department of Environmental Protection. Officials took a wide survey of businesses, fire departments, fire training centers and federal Department of Defense facilities that year as well.
State DEC officials collected 25,000 gallons of PFAS-containing firefighting foam up to 2018.
In 2016, federal officials acknowledged that Fort Drum in Jefferson County had contaminated water near the Wheeler-Sack Army Airfield, resulting in the closure of nearly a half-dozen on-post water wells and a multi-million dollar federal grant to restore water sufficiency on post.
In 2018, officials in New York were expressing disappointment with federal efforts to regulate and address PFAS. The EPA maintains a list of over 100 contaminants that are proven to harm human health, but officials have identified over 80,000 potentially toxic substances to be concerned about.
"The federal government is charged with having a monitoring system to potentially add other chemicals to the ones we are required to test, but the EPA has not been moving fast enough," said Brad J. Hutton, former deputy commissioner for the state Public Health Office, speaking with the Watertown Daily Times in 2018.
Action has come since then. In 2019, the EPA launched a PFAS action plan, outlining a roadmap for addressing chemical contamination in water and soil. In January of 2024, the EPA moved to ban nearly 330 'inactive' PFAS compounds from use or processing without an agency review, effectively taking the substances off the market. Inactive substances are those that aren't used in any major manufacturing, import or export operations in any U.S. territories.
In April 2024, the EPA finalized a rule regulating six PFAS contaminants, including PFOA. The EPA also designated PFOA and PFOS, another similar compound, as hazardous to human health under the terms of the federal 'Superfund' law, allowing for cleanup and cost recovery from polluters.
Questions arose in 2025 over whether the Trump administration would change or drop any of the new regulations adopted after his first term ended in 2021, and in May, the new EPA administrator and former New York gubernatorial candidate Lee Zeldin announced the agency would keep the Biden-era restrictions for PFOA and PFOS, another PFAS chemical, but would drop regulations and reconsider findings for four other substances including PFNA and HDFO-DA.
The latter substance is known colloquially as 'GenX' and was a next-generation replacement to more harmful substances like PFOA. 'GenX' was later found to be similarly harmful to human health, and is similarly able to persist in the environment.
"We are on a path to uphold the agency's nationwide standards to protect Americans from PFOA and PFOS in their water," Zeldin said. "At the same time, we will work to provide common-sense flexibility in the form of additional time for compliance. This will support water systems across the country, including small systems in rural communities, as they work to address these contaminants. EPA will also continue to use its regulatory and enforcement tools to hold polluters accountable."
Zeldin pushed the compliance deadline for the new regulations, and promised to establish an outreach program focused on reaching noncompliant water systems, especially those in rural and small communities, to connect them with resources to bring their projects into compliance with the new rules. The initial rules required water systems to properly filter and remove the six contaminants by 2029, but the changes made by Zeldin push the broad deadline for PFOA and PFOS compliance to 2031.
The EPA also has plans to establish an exemption framework to give noncompliant systems even more time to fix their systems, but the specifics for that aren't out yet.
That move was lauded by some water district officials, including the Association of State Drinking Water Administrators Director, Alan Roberson.
"With the current compliance date of 2029, states and water systems are struggling with the timeframes to complete the pilot testing, development of construction plans, and building the necessary treatment improvements. EPA's proposed extension of the compliance date and increased technical assistance will address the number of systems that would be out of compliance in 2029 due to not being able complete all of these tasks on time," Roberson said.
Most of these changes aren't official yet — the EPA still has to introduce the new rules and usher them through the process, which could be done as early as the spring of next year.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
8 minutes ago
- Medscape
FDA Calls for Better Opioid Safety Labeling
The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication. The changes are based on observations from a May meeting between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, which met to discuss two postmarketing requirement studies that assessed risk for abuse, addiction, and overdose in long-term use of opioid analgesics. One of the observational studies showed that over 12 months of use, 1%-6% of the more than 2000 total participants met criteria for opioid addiction, 9% met criteria for prescription opioid abuse, and 22% met criteria for prescription opioid misuse. In the second study, 5-year cumulative incidence estimates for opioid overdose-related death ranged from 1.5%-4.0%. In addition, 17% of first opioid overdoses over the entire 5-11 year study period were fatal. The new safety-labeling requirements are a result of these findings, committee and public comments from the meeting, and recognition that there is currently an 'absence of adequate and well-controlled studies on long-term opioid effectiveness,' the FDA noted in a press release. 'The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,' FDA commissioner Marty Makary, MD, said in the release. 30-Day Warning The FDA has also called for a new prospective, randomized controlled trial to be conducted that will focus primarily on assessing risks and benefits of opioids used over the long term. For now, the updated labeling should include a better explanation of risks, stronger warnings about higher doses, clarification about use limits, an emphasis that long-acting or extended-release opioids should only be used if shorter-acting opioids or other medications have proven inadequate, and a reminder about serious harm that can come if a patient who becomes physically dependent does not stop opioid use. Additionally, the revised labels should provide information on possible opioid-related problems with the esophagus; on opioid overdose reversal agents; on toxic leukoencephalopathy, which can occur after overdose; and on negative drug-drug interactions, including gabapentinoids. 'This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring,' Makary said. The release noted that OxyContin's drug application was first approved without supportive long-term use data. The FDA added that manufacturers have 30 days to submit the newly required labeling updates for review.


Washington Post
9 minutes ago
- Washington Post
All major Las Vegas Strip casinos are now unionized in historic labor victory
LAS VEGAS — When Susana Pacheco accepted a housekeeping job at a casino on the Las Vegas Strip 16 years ago, she believed it was a step toward stability for her and her 2-year-old daughter. But the single mom found herself exhausted, falling behind on bills and without access to stable health insurance, caught in a cycle of low pay and little support. For years, she said, there was no safety net in sight — until now.
Yahoo
18 minutes ago
- Yahoo
QuidelOrtho (QDEL) Q2 Earnings Report Preview: What To Look For
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) will be reporting results this Tuesday afternoon. Here's what you need to know. QuidelOrtho met analysts' revenue expectations last quarter, reporting revenues of $692.8 million, down 2.6% year on year. It was a mixed quarter for the company, with a solid beat of analysts' EPS estimates but a slight miss of analysts' full-year EPS guidance estimates. Is QuidelOrtho a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting QuidelOrtho's revenue to decline 4.1% year on year to $611 million, in line with the 4.2% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.01 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. QuidelOrtho has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 4.2% on average. Looking at QuidelOrtho's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 3.5%, beating analysts' expectations by 1%, and Hologic reported revenues up 1.2%, topping estimates by 1.7%. GE HealthCare traded down 8.3% following the results while Hologic was up 2.9%. Read our full analysis of GE HealthCare's results here and Hologic's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. QuidelOrtho is down 21.9% during the same time and is heading into earnings with an average analyst price target of $47.14 (compared to the current share price of $22.81). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.